Management of antithrombotic drugs in patients comorbid with cardiovascular disease undergoing urological surgery
10.3760/cma.j.cn112330-20230720-00013
- VernacularTitle:心脏病患者接受泌尿外科手术围手术期抗栓药物管理经验
- Author:
Yong LUO
1
;
Xiaobing YANG
;
Jiahui ZHAO
;
Yongguang JIANG
;
Ning ZHANG
Author Information
1. 首都医科大学附属北京安贞医院泌尿外科，北京 100029
- Keywords:
Urologic surgical procedures;
Cardiovascular comorbidity;
Anticoagulant;
Antiplatelet;
Bridge therapy
- From:
Chinese Journal of Urology
2023;44(11):801-805
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, it has been common for heart disease patients to undergo urological surgery.The requirements for specialized doctors to accurately assess the risk of perioperative heart disease thrombosis are also increasing. In order to conduct multi-disciplinary disease analysis and discussion in a more standardized profile and promote clinical work progress in a safer manner, this article provides a systematic review and summary of the basic characteristics of antithrombotic drugs, the bleeding risks of urological surgery, the risk identification standards for arteriovenous thrombosis, as well as the withdrawal conditions, bridging selection, and restart treatment of perioperative antithrombotic drugs, based on the constantly updated clinical researches and guideline consensuses in recent years.
